Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALLAimee C. Talleur, Stephen Gottschalk, Caitlin Hurley et al.|Blood Advances|2022Cited by 62
Multiple NDM-5-Expressing Escherichia Coli Isolates From an Immunocompromised Pediatric HostTim Flerlage, Randall T. Hayden, Jessica N. Brazelton et al.|Open Forum Infectious Diseases|2020Cited by 20
Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center ExperienceAimee C. Talleur, Stephen Gottschalk, Renee Madden et al.|Blood|2020Cited by 3
Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric PatientsRebecca Epperly, Brandon M. Triplett, Aimee C. Talleur et al.|Transplantation and Cellular Therapy|2022Cited by 3